RxDoctor Payments Data

Ted Brady, DO

Pulmonary Disease · Tamarac, FLNPI 1831150515

Payments from drug & device makers

$6,408in general payments, 2019–2025

Across 362 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$834
  • Sanofi$606
  • Boehringer Ingelheim$568
  • Regeneron Healthcare Solutions, Inc.$494
  • Amgen$237
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$6,408100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,408 in reported general payments places this provider in the 55th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$145,603
Medicare patients
530
Services billed
1,723

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter513$381,617
Breo ElliptaFluticasone/Vilanterol308$142,398
Spiriva RespimatTiotropium Bromide142$80,877
Stiolto RespimatTiotropium Br/Olodaterol Hcl107$60,994
Breztri AerosphereBudesonide/Glycopyr/Formoterol75$56,266
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr91$42,364
SymbicortBudesonide/Formoterol Fumarate127$37,071
Albuterol Sulfate HfaAlbuterol Sulfate625$14,591
Combivent RespimatIpratropium/Albuterol Sulfate24$12,354
Spiriva HandihalerTiotropium Bromide21$10,949
Bevespi AerosphereGlycopyrrolate/Formoterol Fum19$9,497
Arnuity ElliptaFluticasone Furoate29$7,157
Fluticasone-SalmeterolFluticasone Propion/Salmeterol41$6,212
BreynaBudesonide/Formoterol Fumarate33$4,684
Advair DiskusFluticasone Propion/Salmeterol17$4,558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$2,196$573,537941 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$568$154,225273 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$834$102,834221 claims
MerckDulera$36$4,23113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Tamarac

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →